Peripheral Vascular

Covidien has announced that the U.S. Food and Drug Administration (FDA) has expanded the cope of approval for its SpiderFX® embolic protection device to include the treatment of severely calcified lesions used in conjunction with plaque excision in arteries of the lower extremities.